Abstract: A method produces tantalum powder. The method includes: (1) uniformly mixing a tantalum powder raw material, metal magnesium and at least one alkali metal and/or alkaline earth metal halide, loading the mixture into a container, and putting the container in a furnace; (2) raising the temperature of the furnace to 600-1200° C. in the presence of inert gas, and soaking; (3) at the end of soaking, lowering the temperature of the furnace to 600-800° C., vacuumizing the interior of the furnace to 10 Pa or less, soaking under the negative pressure so that the excessive metal is separated; (4) thereafter, raising the temperature of the furnace to 750-1200° C. in the presence of inert gas, and soaking so that the tantalum powder is sintered in the molten salt after oxygen reduction; (5) then cooling to room temperature and passivating to obtain a mixed material containing halide and tantalum powder; and (6) separating the tantalum powder from the resulting mixture.

Abstract: A low-carbon, high-purity tantalum pentoxide powder has a carbon content of no greater than 15 ppm. A preparation method for the powder includes: (1) adding a fluotantalic acid (H2TaF7) solution into a reaction kettle, controlling the temperature of the reaction kettle at 30-60° C., adding a precipitator until the pH of the reaction solution is 8-10, then stopping introducing ammonia, and aging to obtain a tantalum hydroxide slurry; (2) filtering and washing the slurry obtained in step (1), and then carrying out solid-liquid separation to obtain a tantalum hydroxide filter cake; (3) drying the filter cake obtained in step (2) to obtain white tantalum hydroxide powder; (4) calcining the tantalum hydroxide powder obtained in step (3), crushing and screening the calcined sample to obtain tantalum pentoxide powder; and (5) subjecting the tantalum pentoxide powder obtained in step (4) to heat treatment at a temperature of 1000-1500° C. to obtain the powder.

Abstract: The present disclosure provides a method for aligning a master oscillator power amplifier (MOPA) system. The method includes ramping up a pumping power input into a laser amplifier chain of the MOPA system until the pumping power input reaches an operational pumping power input level; adjusting a seed laser power output of a seed laser of the MOPA system until the seed laser power output is at a first level below an operational seed laser power output level; and performing a first optical alignment process to the MOPA system while the pumping power input is at the operational pumping power input level, the seed laser power output is at the first level, and the MOPA system reaches a steady operational thermal state.

Abstract: A wideband vibration suppression device utilizing properties of a sonic black hole, comprising: a vibration absorber (101) comprising a uniform portion (1011) of a fixed thickness and a conical portion (1012) integrally connected to the uniform portion (1011), the conical portion (1012) extending from the junction in such a manner that the thickness thereof gradually decreases from the thickness (d1) of the uniform portion (1011) to a predetermined thickness (d2); and a damping layer (102) attached to the conical portion (1012) of the vibration absorber (101).

Abstract: A vaporizer comprises an absorber and a heating element. The absorber is configured to absorb the material to be vaporized and comprises a plurality of first pores of a 100-500 nm diameter and a plurality of second pores of a 20-100 nm diameter. A ratio of the number of the second pores N2 to the number of the first pores N1 in a unit area, i.e., N2/N1, is 10-50%. The heating element heats and vaporizes the material to be vaporized in the absorber.

Abstract: Provided are an enterovirus D68 (EV-D68) or a modified form thereof, or a nucleic acid molecule comprising a genomic sequence or cDNA sequence of the EV-D68 or a modified form thereof, or a complementary sequence of the genomic sequence or cDNA sequence, or a pharmaceutical composition comprising the EV-D68 or a modified form thereof, or the nucleic acid molecule, and use of the EV-D68 or a modified form thereof, or the nucleic acid molecule in the manufacture of a pharmaceutical composition for treating a tumor.

Abstract: An apparatus for mounting devices onto a surface is disclosed. In some implementations, the apparatus comprises a base portion and a top portion. The base portion can support a number of sections that can be independently assembled in some implementations. The top portion may be compatible or compliant with VESA standards in some implementations. The top portion may be adjustable, tiltable, or rotatable in some implementations. In some implementations, a hollow interior of the apparatus may facilitate cable and/or wire management. In some implementations, the geometry of the apparatus can enable the weight of the device to pass directly through the center of gravity of apparatus, thereby ensuring the stability of the apparatus and the device.

Abstract: An apparatus for securely mounting devices onto a variety of surfaces is disclosed. In some implementations, the apparatus comprises a surface mounting plate and a device mounting plate. In some implementations, the device mounting plate is compliant or compatible with VESA standards. In some implementations, the surface mounting plate and the device mounting plate are assembled together. In some implementations, the surface mounting plate can be secured against unauthorized removal. In some implementations, the surface mounting plate can allow electricity to pass from a connected electric source to the assembled apparatus so as to enable a device mounted on the assembly to receive power, data, and/or other signals. In some of the implementations, the apparatus enables the provision of cordless, wireless, or inductive charging.

Abstract: A model and an application thereof, the model being used for detecting a benign and malignant degree of a tumor. The model grades a change of an imprinted gene in a tumor by calculating a deletion expression quantity of the imprinted gene and a copy number abnormal expression quantity of the imprinted gene. The detection model and device in the present invention presents the expression of loss of imprinting in a sample of a tumor patient in a direct way for the first time; based on an imprinted gene in situ labeling method, a change of an imprinted gene is detected objectively, directly, early, and precisely, and a quantitative model can be provided, to make a great contribution to molecular pathology diagnosis.

Abstract: Provided are use of an Echovirus 25 (ECHO25) or a modified form thereof, or a nucleic acid molecule comprising a genomic sequence or cDNA sequence of the ECHO25 or a modified form thereof, or a complementary sequence of the genomic sequence or cDNA sequence, in treatment of a tumor in a subject, and in the manufacture of a medicament for treatment a tumor in a subject.

Abstract: Disclosed are a fusion protein probe and a cell model for screening a blocking agent of coronavirus infections, a screening system comprising same, and a method of using the screening system for screening a blocking agent of coronavirus infections. The screening system and method do not involve live viruses, are simple and convenient to operate, have a high accuracy, are suitable for high throughput screening, and are of great significance for the development of coronavirus neutralizing antibodies, preventive vaccines, and small molecule drugs.

Abstract: An electronic device includes a light emitting assembly, a fingerprint chip, and a plurality of color filters. The light emitting assembly is disposed between encapsulation glass and a glass substrate of a display of the electronic device; the fingerprint chip is provided with a plurality of filter sub-regions that are spaced apart from each other; and the plurality of color filters are disposed between the display and the plurality of filter sub-regions respectively.

Abstract: A display assembly and a display device are provided. The display assembly includes: a display panel; a diverging piece, arranged on a side of the display panel in a width direction; an emitting module, arranged on a non-display side of the display panel and configured to emit light to the diverging piece; a receiving module, arranged on the non-display side of the display panel and configured to receive light reflected by a detection target; and a cover plate, arranged on a display side of the display panel. The diverging piece is configured to diverge the emitted light to the detection target. A stretching structure is formed on one of the cover plate or the diverging piece. The stretching structure is located on the side of the display panel in the width direction. The stretching structure stretches light diverged by the diverging piece in the width direction of the display panel.

Abstract: A display assembly includes: a display panel; a cover plate, disposed on a display side of the display panel; a diverging element, located on a side of the cover plate close to the display panel, where the diverging element is disposed in a non-display region of the cover plate and is configured to diverge received light and emit diverged light; an emission module, configured to emit light, where the emission module is disposed on a non-display side of the display panel and faces the diverging element; and a receiving module, disposed on the non-display side of the display panel and configured to receive reflected light that is formed by a detection target through reflecting light diverged by the diverging element.

Abstract: This application provides a tumor marker and its applications. The tumor marker includes any one, or a combination of at least two, of imprinted genes Z17, Z18, Z19, Z20, Z21, Z22, Z23, Z25, Z26, Z27, and Z28. If necessary, the tumor marker may further include any one, or a combination of at least two, of imprinted genes Z1, Z2, Z3, Z4, Z5, Z6, Z8, Z9, Z10, N11, Z12, Z13, Z14, Z15, and N16. The imprinted genes in this application have significant diagnostic sensitivity when used as tumor markers for tumor diagnosis and can therefore facilitate early diagnosis of tumors, help increase patients' survival rates, and thus contribute greatly to saving patients' lives. The imprinted genes can also provide important guidance on the treatment and medication of tumors.

Abstract: Disclosed are a grading model for detecting the benign and malignant degree of skin tumors and an application thereof. The model grades changes of imprinted genes in tumors by calculating the expression of the loss of imprinting of the imprinted genes, the expression of the copy number variation of the imprinted genes and the total expression of the imprinted genes. The detection model and device intuitively express the presentation of the loss of imprinting on tissue and cell samples of patients with skin tumors, detect the changes of imprinted genes by means of in-situ marking objectively, intuitively and accurately in an early phase, provide a quantitative model, and make a great contribution to the diagnosis of skin tumors.

Abstract: Provided are quinoline derivative compounds of Formulae (I), (II) and (III) with an inhibitory effect on mTOR and applications of their pharmaceutically acceptable salts, their stereoisomers, their hydrates or their solvates in preparation of medicine for preventing and/or treating diseases caused by enteroviruses.

Abstract: The present application falls within the field of medical technology, and in particular relates to the use of 9-[3-(6-amino)-pyridyl]-1-[(3-trifluoromethyl)-phenyl]benzo[h][1,6]naphthyridine-2(1H)-one (Formula I), and a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a hydrate or a solvate thereof, and a pharmaceutical composition containing the compound, which composition is used for resisting a wide spectrum of viruses, and especially relates to the use thereof for treating enterovirus infections.

Abstract: The present application provides a prognostic marker for lung cancer, a prognostic typing model for lung cancer, and applications thereof. The marker includes imprinted genes Dcn, Peg10, Snrpn/Snurf, and Trappc9. The four imprinted genes Dcn, Peg10, Snrpn/Snurf, and Trappc9 used in the present application have a significant correlation with lung cancer prognosis. Imprinted gene Dcn is the most sensitive and most specific marker for lung cancer prognosis and can serve an indicative purpose earlier than clinicopathologic features. The product of a total expressed quantity of each of the four imprinted genes and an expressed quantity of the imprinted gene with a copy number variation contributes to creating the prognostic typing model for lung cancer, thereby enabling the prediction of the five-year survival rates of individual lung cancer patients and the provision of accurate, useful prognosis information to lung cancer patients.

Abstract: A vaporizer comprises an absorber, a heating element, and a porous cover layer. The absorber is configured to absorb a material to be vaporized. The heating element is configured to heat and vaporize the material to be vaporized in the absorber, and includes a first electrode portion, a second electrode portion, and an electrically conductive connecting member connected between the first electrode portion and the second electrode portion. The porous cover layer covers at least a portion of the heating element without covering the first and second electrode portions. A ratio of an area of the porous cover layer to an area of the electrically conductive connecting member is defined as a covering ratio, which is at least 50%. A porosity of the porous cover layer ranges from 30% to 75%.